Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Lenz, H Philip, P Saunders, Mark P Kolevska, T Mukherjee, K Samuel, L Bondarde, S Dobbs, T Tagliaferri, M Hoch, U
Lenz, H
Philip, P
Saunders, Mark P
Kolevska, T
Mukherjee, K
Samuel, L
Bondarde, S
Dobbs, T
Tagliaferri, M
Hoch, U
Citations
Altmetric:
Abstract
Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (mCRC).
Description
Date
2017-12
Publisher
Collections
Keywords
Type
Article
Citation
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. 2017, 80(6): 1161-1169 Cancer Chemother Pharmacol